UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549


                                   FORM 10-QSB

[X]  Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange
     Act of 1934

         For the quarterly period ended June 30, 1999

[]   Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of
     1934

         For the transition period from                       to

Commission File Number 001-14297

                                MW Medical, Inc.
        (Exact name of Small Business Issuer as specified in its charter)

           Nevada                                       86-0907471
(State or other jurisdiction of                        (IRS Employer
      incorporation )                                Identification No.)

       6955 East Caballo Drive
       Paradise Valley, Arizona                                 85253
(Address of principal executive offices)                     (Zip Code)

Issuer's telephone number, including area code:  (602) 483-8700

Indicate by a check mark  whether the issuer (1) has filed all reports  required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days. [X] Yes [ ] No

Indicate the number of shares  outstanding  of each of the  issuer's  classes of
common stock, as of the latest practicable date.

              Class                         Outstanding as of June 30, 1999
------------------------------------        --------------------------------
$.001 par value Class A Common Stock                 16,723,929 shares



                                        1

<PAGE>



                         PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

BASIS OF PRESENTATION

General
The accompanying unaudited financial statements have been prepared in accordance
with  the  instructions  to Form  10-QSB  and,  therefore,  do not  include  all
information  and footnotes  necessary for a complete  presentation  of financial
position,  results  of  operations,  cash  flows,  and  stockholders'  equity in
conformity  with generally  accepted  accounting  principles.  In the opinion of
management,  all adjustments considered necessary for a fair presentation of the
results of  operations  and  financial  position have been included and all such
adjustments  are of a normal  recurring  nature.  Operating  results for the six
months ended June 30, 1999, are not  necessarily  indicative of the results that
can be expected for the year ending December 31, 1999.

Item 2. Management's  Discussion and Analysis of Financial Condition and Results
        of Operations.

MW Medical,  Inc. (the "Company") is in the business of designing and developing
microwave technologies for dermatological  applications through its wholly owned
subsidiary,  Microwave  Medical  Corporation  ("MMC").  The  Company is a Nevada
corporation and was incorporated on December 4, 1997.

The Company's products are in the development stage. The Company plans to market
and sell its microwave  technology  products upon  completion of the development
stage.

The Company was originally the owner of two wholly owned subsidiaries:

          (A)  Microwave Medical Corporation, a California corporation ("MMC");

          (B)  P&H Laboratories, Inc., a California corporation ("P&H").

Sale of the Business of P&H and Default on Note Payment by Purchaser
The Company has sold the business of P&H pursuant to an asset  purchase and sale
agreement   dated  March  9,  1998  between  P&H  and  Microwave   Communication
Corporation, a California corporation ("Microwave"),  whereby P&H agreed to sell
to Microwave  all of the assets of the  business of P&H as a going  concern (the
"P&H Sale  Agreement").  The sale of assets by P&H to Microwave was completed on
May 6, 1998. The following consideration was received by the Company on closing:

          (A)  cash consideration of $160,943;

          (B)  a  promissory  note  issued  by  MCC/  Ferro  Systems,   Inc.,  a
               subsidiary of Microwave,  whereby  MCC/Ferro has agreed to pay to
               P&H the sum of $250,000 on August 1, 1998 and the sum of $243,125
               on March 31,  1999 (the  "MCC/Ferro  Promissory  Note");  P&H has
               assigned the note to the Company;

          (C)  the  agreement  of  Microwave  to  provide  to MMC 1200  hours of
               microwave  related  services  for the  period  to April 1,  1999,
               subject to a maximum of 100 hours per month;

          (D)  office space for the business of MMC at  MCC/Ferro's  facility in
               Simi Valley, California until February 28, 1999.

The obligations of MCC/Ferro under the MCC/ Ferro Promissory Note are secured by
a general security  agreement  against the assets of MCC/Ferro and the guarantee
of Microwave.  The general security  agreement is subordinated to bank financing
arranged by MCC/Ferro to pay-out P&H's bank  financing and pay the amounts under
the MCC/Ferro Promissory Note.



                                        2

<PAGE>



The payment  was not  received on March 31,  1999.  The Company has  recorded an
allowance for doubtful accounts of $60,000 and extended the repayment terms. MCC
is to make  monthly  payments of $15,000  including  interest at 8% beginning in
July on the  principal  balance of $243,125.  MCC is currently in default of its
July and August payments.

Recent Activities of Microwave Medical Corporation

The Company's  wholly owned  subsidiary,  MMC, is engaged in the  development of
proprietary  technology  relating  to the use of  microwave  energy for  medical
applications.  MMC has a patent  pending  entitled,  "Method and  Apparatus  for
Treating Subcutaneous  Histological Features",  which focuses on the application
of  microwave  energy  to the  treatment  of  spider  veins  and for use in hair
removal.  The use of  microwave  for hair  removal is based  upon the  selective
heating of hair  follicles  while cooling the surface of the skin to protect the
epidermis. MMC has used computer modeling and laboratory studies to optimize the
system  for hair  removal.  Preclinical  studies  have  shown  effectiveness  in
destroying follicles while maintaining the integrity of the skin surface.

MMC's microwave  system for hair removal has completed Phase III clinical trials
and the  Company  has  sufficient  data to  submit  for the  U.S.  Food and Drug
Administration  (FDA) approval.  In April 1999, the Company filed the first in a
series of FDA 510(k)  submissions for its proprietary  microwave  technology for
minimally  invasive  cosmetic  surgery.  The 510(k) will focus on the use of the
Company's microwave device for hair removal.

In  May  1999,  the  Company  received  IRB  approval  from  Independent  Review
Consulting, Inc. to conduct Phase II clinical trials for the treatment of spider
veins  (telangiectasias)  in the legs  using the  Company's  microwave  delivery
system.

Liquidity And Capital Resources

As of June 30,  1999,  the  Company had  $918,002 in cash and cash  equivalents.
During the six months ended June 30, 1999, the Company received cash of $750,000
and incurred  capital  raising costs of $75,000 in  connection  with the sale of
1,000,000 shares of the Company's  restricted  common stock. Loss per share from
research  operations,  general and administrative  expenses and depreciation and
amortization was $.05.

Subsequent  to June  30,  the  Company  raised  $3  million  from the sale of 8%
convertible debentures due July 31, 2000 to a number of investor/purchasers sold
pursuant to an exemption from registration under Rule 506 of Regulation D of the
Securities  Act of 1933.  Under the  Purchase  Agreement  for these  convertible
debentures,  the purchasers obtained warrants for the purchase of 350,000 shares
of the  Company's  common  stock at a price  of $2.50  per  share,  and  certain
registration  rights.  Certain of the  purchasers  also  agreed to  purchase  an
additional $500,000 of the convertible  debentures following registration of the
securities.  A large number of the purchasers  exercised their option to convert
their debentures into common stock shortly after purchase.

Results of Operations

The financial statements for 1999 present the combined activities of the Company
and MMC.

The  financial  statements  for 1998  present  the  combined  activities  of the
Company, MMC, and P&H for the first quarter.

Second Quarter 1999 Compared with Second Quarter 1998

During the three  months  ended June 30,  1999,  the  management  of the Company
received  $105,000.  The President  received $36,000,  the Chairman of the Board
received $45,000 and the  Secretary/Treasurer  received  $24,000.  The President
resigned  on July 9, 1999 and was  replaced by the  Chairman,  who now serves as
President, C.E.O., and Chairman of the Board.

Net loss for the three  months  ended June 30, 1999 was  $386,409  compared to a
loss of $771,596 for the same period in 1998. The higher loss in 1998 was due to
the sale of its  subsidiary,  P&H. If the Company  receives  FDA approval on its
microwave hair removal  process,  it expects to generate revenue in late 1999 or
early 2000.


                                        3

<PAGE>



General and  administrative  expenses  for the three  months ended June 30, 1999
were  $222,785  compared to $86,249 for the same  period in 1998.  In 1998,  the
Company  concentrated  in the  development  of its  technology  and was  able to
minimize all administrative cost whereas in 1999, the assembly of its management
team and staff increased expenditures.

Research and development  expenses were $144,636 for the three months ended June
30,  1999  compared  to  $159,783  for the same  period  in 1998.  Research  and
development cost has remained fairly constant.

Depreciation and amortization  expenses for the three months ended June 30, 1999
were $24,672  compared to $25,282 for the same period in 1998.  Depreciation  of
its equipment is taken on a straight-line method of between 3 and 5 years.

First Six Months Fiscal 1999 Compared with First Six Months Fiscal 1998

During the six  months  ended  June 30,  1999,  the  management  of the  Company
received $210,000. The President received $72,000, the Chairman received $90,000
and the Secretary/Treasurer received $48,000.

Net loss for the six months ended June 30, 1999 was $775,975  compared to income
of $1,185,495 for the same period in 1998. The income  generated in 1998 was due
to the cancellation of its $2 million debt from MMC's former parent, Dynamic.

General and administrative  expenses for the six months ended June 30, 1999 were
$477,320  compared to $87,304 for the same period in 1998. In 1999,  the Company
has been assembling key executives for growth.

Research and  development  expenses  were $262,151 for the six months ended June
30, 1999 compared to $351,940 for the same period in 1998. R&D costs were higher
in 1998 due to the additional testing site of the Company's German subsidiary.

Depreciation  and  amortization  expenses for the six months ended June 30, 1999
were $49,344 compared to $50,564 for the same period in 1998.

Impact of the Year 2000 Issue
The "Year 2000 problem" arose because many existing  computer  programs use only
the last two digits to refer to a year.  Therefore,  these computer  programs do
not  properly  recognize a year that begins  with "20"  instead of the  familiar
"19".  If not  corrected,  many  computer  applications  could  fail  or  create
erroneous  results.  The extent of the potential impact of the Year 2000 problem
is not yet  known,  and if not  timely  corrected,  it could  affect  the global
economy.  The Company believes that its computer  programs are Y2K compliant and
does not expect to be adversely  affected by the issue. The Company is presently
identifying  and assessing the year 2000  readiness of its key suppliers that we
believe to be significant to the Company's business operations. At this point in
time,  the Company's one possible  worst case scenario  would be that certain of
the Company's material suppliers or vendors experience business  disruptions due
to the year 2000 issue and are unable to provide  materials  and services to the
Company on time.

                           PART II - OTHER INFORMATION

Item 6. Exhibits and Reports on Form 8-K

     (a) Exhibits
         99-1 Financial Statements as of June 30, 1999.
         Financial Data Schedule

     (b) Reports on Form 8-K
         None.




                                        4

<PAGE>



                                   SIGNATURES

     Pursuant to the  requirements  of the  Securities and Exchange Act of 1934,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                    MW Medical, Inc.

DATED:  August 23, 1999
                                    Grace Sim, Secretary/Treasurer and Director


                                        5

<PAGE>



                        MW MEDICAL, INC. AND SUBSIDIARIES
                           CONSOLIDATED BALANCE SHEETS



<TABLE>
<CAPTION>
                                                                                                 June 30,          December 31,
                                                                                                   1999                1998
                                                                                                (Unaudited)          (Audited)
                                                                                             -----------------  ------------------
ASSETS
   CURRENT ASSETS
<S>                                                                                          <C>                <C>
     Cash and cash equivalents                                                               $         918,002  $          890,283
     Receivable - former parent                                                                        150,000             200,000
     Receivable - P & H sale                                                                           106,570              21,625
     Other receivables                                                                                   4,990               2,000
     Prepaid expense and other current assets                                                           14,258              61,282
                                                                                             -----------------  ------------------
                                                                      TOTAL CURRENT ASSETS           1,193,820           1,175,190

   PROPERTY, PLANT, & EQUIPMENT                                                                        918,168              67,392

   OTHER ASSETS
     Receivable - P&H sale                                                                              76,555             161,500
     Organization costs                                                                                    280                 400
                                                                                             -----------------  ------------------
                                                                                                        76,835             161,900
                                                                                             -----------------  ------------------

                                                                                             $       2,188,823  $        1,404,482
                                                                                             =================  ==================

LIABILITIES & EQUITY
   CURRENT LIABILITIES
     Accounts payable                                                                        $         524,180  $           70,766
     Loan payable                                                                                      425,000                   0
     Income taxes payable                                                                                  800               1,600
     Accrued expenses                                                                                    1,449               1,038
     Deposits                                                                                           10,000                   0
     Accrued expenses - related party                                                                  130,005             132,714
                                                                                             -----------------  ------------------
                                                                 TOTAL CURRENT LIABILITIES           1,091,434             206,118
                                                                                             -----------------  ------------------

                                                                         TOTAL LIABILITIES           1,091,434             206,118

STOCKHOLDERS' EQUITY
   Common stock $.001 par value:
     Authorized - 100,000,000 shares
     Issued and outstanding 16,723,929 shares (15,723,929 in 1998)                                      16,724              15,724
     Additional paid in capital                                                                      1,729,997           1,055,997
   Retained earnings (deficit)                                                                        (649,332)            126,643
                                                                                             -----------------  ------------------
                                                                TOTAL STOCKHOLDERS' EQUITY           1,097,389           1,198,364
                                                                                             -----------------  ------------------

                                                                                             $       2,188,823  $        1,404,482
                                                                                             =================  ==================
</TABLE>



                                      F - 1

<PAGE>



                        MW MEDICAL, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (Unaudited)


<TABLE>
<CAPTION>
                                                                       Three months ended                  Six months ended
                                                                            June 30,                           June 30,
                                                                -------------------------------    -------------------------------
                                                                     1999             1998              1999             1998
                                                                -------------     -------------    -------------     -------------
<S>                                                             <C>               <C>              <C>               <C>
General & administrative expenses                               $     222,785     $      86,249    $     477,320     $      87,304
Depreciation and amortization                                          24,672            25,282           49,344            50,564
Research and development                                              144,636           159,783          262,151           351,940
                                                                -------------     -------------    -------------     -------------
                                                                      392,093           271,314          788,815           489,808
                                                                -------------     -------------    -------------     -------------

                                        NET OPERATING (LOSS)         (392,093)         (271,314)        (788,815)         (489,808)

OTHER INCOME (EXPENSE)
   Interest income                                                      5,684               580           13,640               627
   Debt cancellation - former parent                                        0                 0                0         2,169,806
   Fee - former parent                                                      0                 0                0           200,000
   Sale of subsidiary                                                       0          (500,862)               0          (500,862)
                                                                -------------     -------------    -------------     -------------
                                                                        5,684          (500,282)          13,640         1,869,571
                                                                -------------     -------------    -------------     -------------

Income (loss) from continuing operations before
   income taxes                                                      (386,409)         (771,596)        (775,175)        1,379,763
Income tax expense                                                          0                 0              800               800
                                                                -------------     -------------    -------------     -------------

                                    NET INCOME (LOSS) BEFORE
                                     DISCONTINUED OPERATIONS         (386,409)         (771,596)        (775,975)        1,378,963

Discontinued operations:
   Operations of subsidiary sold 4/1/98                                     0                 0                0          (193,468)
                                                                -------------     -------------    -------------     -------------

                                           NET INCOME (LOSS)    $    (386,409)    $    (771,596)   $    (775,975)    $   1,185,495
                                                                =============     =============    =============     =============

Net income (loss) per weighted average share                    $        (.02)    $        (.05)   $        (.05)    $         .08
                                                                =============     =============    =============     =============

Weighted average number of common shares used
   to compute net income (loss) per weighted
   average share                                                   16,232,262        14,223,929       16,003,096        14,223,929
                                                                =============     =============    =============     =============

</TABLE>


                                      F - 2

<PAGE>



                        MW MEDICAL, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (Unaudited)


<TABLE>
<CAPTION>
                                                                                                    Six months ended
                                                                                                        June 30,
                                                                                               1999                  1998
                                                                                        ------------------    ------------------
OPERATING ACTIVITIES
<S>                                                                                     <C>                   <C>
     Net income (loss)                                                                  $         (775,975)   $        1,185,495
     Adjustments to reconcile net income (loss) to cash used
       by operating activities:
         Depreciation and amortization                                                              49,344                89,141
         Net value of subsidiary sold                                                                    0             1,398,034
         Debt cancelled                                                                                  0            (2,169,806)
     Changes in assets and liabilities:
         Accounts receivable                                                                        47,010              (683,519)
         Inventories                                                                                     0                80,636
         Prepaid expenses and other                                                                 47,024              (166,791)
         Accounts payable and accrued expenses                                                     451,116                (7,756)
         Deposits                                                                                   10,000                37,000
         Income taxes payable                                                                         (800)                    0
                                                                                        ------------------    ------------------

                                               NET CASH USED BY OPERATING ACTIVITIES              (172,281)             (237,566)

INVESTING ACTIVITIES
     Loan - other                                                                                        0                (6,231)
     Purchase of equipment                                                                        (900,000)               (1,796)
     Deposits                                                                                            0                (2,225)
                                                                                        ------------------    ------------------

                                               NET CASH USED BY INVESTING ACTIVITIES              (900,000)              (10,252)

FINANCING ACTIVITIES
     Borrowings - former parent                                                                          0               170,000
     Loans                                                                                         425,000                     0
     Cash remaining with former subsidiary                                                               0              (243,102)
     Sale of common stock                                                                          675,000                     0
     Principal payments on debt                                                                          0                (9,951)
                                                                                        ------------------    ------------------

                                                                   NET CASH PROVIDED
                                                             BY FINANCING ACTIVITIES             1,100,000               (83,053)
                                                                                        ------------------    ------------------

                                                         INCREASE (DECREASE) IN CASH
                                                                AND CASH EQUIVALENTS                27,719              (330,871)

     Cash and cash equivalents at beginning of period                                              890,283               387,982
                                                                                        ------------------    ------------------

                                          CASH AND CASH EQUIVALENTS AT END OF PERIOD    $          918,002    $           57,111
                                                                                        ==================    ==================

SUPPLEMENTAL INFORMATION
     Cash paid for interest                                                             $            3,963    $            9,824
     Cash paid for income taxes                                                                      1,600                   800

</TABLE>


                                      F - 3